Abpro Holdings, Inc. (ABP)

NASDAQ: ABP · Real-Time Price · USD
0.4200
+0.0084 (2.04%)
At close: Mar 28, 2025, 4:00 PM
0.4298
+0.0098 (2.33%)
After-hours: Mar 28, 2025, 7:50 PM EDT
2.04%
Market Cap 21.22M
Revenue (ttm) 230,000
Net Income (ttm) -7.72M
Shares Out 50.52M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,700
Open 0.4116
Previous Close 0.4116
Day's Range 0.4116 - 0.4500
52-Week Range 0.4100 - 13.0000
Beta -0.29
Analysts Strong Buy
Price Target 4.00 (+852.38%)
Earnings Date May 18, 2025

About ABP

Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 16
Stock Exchange NASDAQ
Ticker Symbol ABP
Full Company Profile

Financial Performance

In 2023, Abpro Holdings's revenue was $122,000, a decrease of -93.99% compared to the previous year's $2.03 million. Losses were -$11.71 million, -32.00% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ABP stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(852.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...

3 days ago - GlobeNewsWire

Abpro Statement on the Departure of Former CEO Ian Chan

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...

18 days ago - GlobeNewsWire

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening di...

3 months ago - GlobeNewsWire